

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Romiplostim for the treatment of thrombocytopenic purpura

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators for the appraisal of romiplostim for the treatment of thrombocytopenic purpura

Issue date: August 2008

1.	<p><i>I would like to see an ITP specialist included in the consultees.</i></p> <p><i>As all of our medical advisors appear to have a conflict of interest having worked for NICE or one of the drug companies involved, I have attached a statement of support from Professor James George.</i></p>	<p><i>ITP Support Association</i></p>	<p><i>Not Added</i></p>	<p><i>We do not currently use individual person's on our matrices therefore an individual of the ITP Support Association has not been included as per our inclusion criteria and equalities commitments.</i></p>
----	--	---------------------------------------	-------------------------	--

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators for the appraisal of romiplostim for the treatment of thrombocytopenic purpura

Issue date: August 2008

2.	<i>PIIP would like you to consider:</i> NCH – The children's charity	<i>PIIP</i>	<i>Not added</i>	<i>This organisation's interests are not closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore NCH – The children's charity have not been included.</i>
----	---	-------------	------------------	--

National Institute for Health and Clinical Excellence

Response to comments on the matrix of consultees and commentators for the appraisal of romiplostim for the treatment of thrombocytopenic purpura

Issue date: August 2008